ND Committee Review
Internal Medical Policy Committee 9-26-2019 Adopted new policy
Internal Medical Policy Committee 11-14-2019 Added 18 years of age or older to criteria
Internal Medical Policy Committee 5-19-2020 Changed J9145 to pre-certification drug
Internal Medical Policy Committee 7-22-2020 Added daratumumab and hyaluronidase-fihj (Darzalex Faspro) to policy, added one additional daratumumab (Darzalex) FDA indication to policy
Internal Medical Policy Committee 9-21-2020 Added new code, C9062, to policy
Internal Medical Policy Committee 1-19-2021 Added new code J9144 and removed C9062 from policy effective 1-1-2021
Internal Medical Policy Committee 5-21-2021 Updated FDA indications and NCCN recommendations for daratumumab (Darzalex) and daratumumab and hyaluronidase-fihj (Darzalex Faspro)
Internal Medical Policy Committee 5-24-2022 Annual review, no clinical content change